Novo Nordisk revenue and financials
kr 250.35Change from previous close: +1.95%Absolute change: +kr 4.80
In the fiscal year ended December 2025, Novo Nordisk reported revenue of kr 309.06B (+6.43% year over year). Net income was kr 102.43B, a net margin of 33.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.43%
- 2025 vs 2024
- Net income growth
- +1.43%
- 2025 vs 2024
- Net margin
- 33.1%
- 2024: 34.8%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 78,488 | 96,823 | 79,144 | 74,976 | 76,857 | 78,087 | 85,683 | 71,311 | 68,060 | 65,349 | 65,863 | 58,731 |
| Cost of revenue | 17,100 | 13,598 | 14,170 | 14,471 | 12,846 | 12,890 | 12,062 | 11,308 | 10,274 | 9,916 | 9,568 | 9,713 |
| Gross profit | 61,388 | 83,225 | 64,974 | 60,505 | 64,011 | 65,197 | 73,621 | 60,003 | 57,786 | 55,433 | 56,295 | 49,018 |
| Selling, general and administrative | 16,306 | 13,217 | 17,143 | 15,761 | 18,849 | 16,112 | 20,272 | 16,592 | 16,091 | 14,413 | 18,622 | 14,075 |
| Research and development | 11,459 | 10,284 | 12,671 | 11,490 | 11,690 | 10,308 | 5,812 | 9,488 | 10,466 | 8,606 | 9,092 | 8,128 |
| Operating income | 33,389 | 59,618 | 35,241 | 33,254 | 33,449 | 38,791 | 47,299 | 33,822 | 31,634 | 31,846 | 28,890 | 26,913 |
| EBIT | 33,389 | 59,618 | 35,241 | 33,254 | 33,449 | 38,791 | 47,299 | 33,822 | 31,634 | 31,846 | 28,890 | 26,913 |
| EBITDA | 36,994 | 63,131 | 36,655 | 36,491 | 37,193 | 42,550 | 47,875 | 35,842 | 33,671 | 34,003 | 30,346 | 29,438 |
| Interest expense | 1,500 | 3,499 | 4,966 | — | 4,958 | 5,183 | 400 | — | 1,562 | 1,998 | 1,630 | 2,168 |
| Pre-tax income | 26,875 | 62,172 | 34,185 | 25,517 | 33,805 | 37,033 | 35,557 | 34,384 | 25,332 | 31,918 | 27,620 | 28,063 |
| Income tax | 5,886 | 13,615 | 7,294 | 5,511 | 7,302 | 7,999 | 7,327 | 7,083 | 5,282 | 6,511 | 5,657 | 5,585 |
| Net income | 20,989 | 48,557 | 26,891 | 20,006 | 26,503 | 29,034 | 28,230 | 27,301 | 20,050 | 25,407 | 21,963 | 22,478 |
| Net income to common shareholders | 20,989 | 48,557 | 26,891 | 20,006 | 26,503 | 29,034 | 28,230 | 27,301 | 20,050 | 25,407 | 21,963 | 22,478 |
| Basic EPS | 4.74 | 10.93 | 6.05 | 4.50 | 5.96 | 6.54 | 6.35 | 6.13 | 4.50 | 5.70 | 4.92 | 5.02 |
| Diluted EPS | 4.73 | 10.91 | 6.04 | 4.50 | 5.96 | 6.53 | 6.34 | 6.12 | 4.49 | 5.68 | 4.91 | 5.00 |
| Average shares (basic) | 4,428 | 4,443 | 4,444 | 4,444 | 4,447 | 4,439 | 4,446 | 4,452 | 4,458 | 4,460 | 4,465 | 4,477 |
| Average shares (diluted) | 4,436 | 4,449 | 4,449 | 4,447 | 4,447 | 4,446 | 4,456 | 4,461 | 4,465 | 4,471 | 4,477 | 4,489 |
| Dividend per share | 3.75 | — | 7.95 | — | 3.75 | — | 7.90 | — | 3.50 | — | 6.40 | — |